Nevertheless, our study suggests that IGFBP1 can be regarded as a potential biomarker for lung cancer survival and that increased IGFBP1 could enhance compatibility with current treatment regimens for lung cancer. This evidence concerns the gene IGFBP1 and lung cancer.